Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | VHL | P40337 | 1/20 | 0.39 |
| ▸ | ELOC | Q15369 | 1/20 | 0.39 |
| ▸ | ELOB | Q15370 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543406 | 1.00 | MEN1 (0.46) | MEN1KMT2AL3MBTL1NOTUMMAOB | |
| SCHEMBL12316699 | 0.82 | LMNA (0.42) | MEN1KMT2AL3MBTL1MAOBVHL | |
| SCHEMBL12316746 | 0.82 | MAOB (0.44) | MEN1KMT2AL3MBTL1MAOBVHL | |
| SCHEMBL6582453 | 0.82 | SIRT2 (0.38) | MEN1KMT2AL3MBTL1MAOBVHL | |
| SCHEMBL10741838 | 0.82 | SIRT2 (0.44) | MEN1KMT2AL3MBTL1NOTUMMAOB | |
| SCHEMBL87071 | 0.82 | MAOB (0.37) | MEN1KMT2AL3MBTL1NOTUMMAOB | |
| SCHEMBL8191575 | 0.82 | MAOB (0.37) | MEN1KMT2AL3MBTL1MAOBVHL | |
| SCHEMBL14053377 | 0.82 | NOTUM (0.42) | MEN1KMT2AL3MBTL1NOTUMMAOB | |
| SCHEMBL12316580 | 0.82 | SIRT2 (0.47) | MEN1KMT2AL3MBTL1MAOBVHL | |
| SCHEMBL8176937 | 0.81 | NOTUM (0.48) | MEN1KMT2AL3MBTL1NOTUMMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| JP-63183579-A | — | — | None | — | — | JP | disclosed |
| CN-116496261-A | 4- (1H) -imidazole derivative and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-07-28 | — | — | CN | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| EP-2053095-B2 | Ink composition and inkjet recording method using the same | FUJIFILM CORP (JP) | 2017-02-22 | — | — | EP | disclosed |
| EP-2209790-B1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| EP-0613618-A1 | Method for safening herbicides in crops using substituted benzopyran and tetrahydronaphthalene compounds | AMERICAN CYANAMID COMPANY (US) | 1994-09-07 | — | — | EP | disclosed |
| JP-S63183579-A | NOVEL 2H-1-BENZOPYRAN DERIVATIVE | SS PHARMACEUT CO LTD | 1988-07-28 | — | — | JP | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4065574-A | New method for controlling fungi using 4-chromone, 4-chromanone, 4-chromone oxime and 4-chromanone oxime compounds | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | MEN1 2418/4885KMT2A 1195/4885L3MBTL1 232/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | MEN1 2418/4885KMT2A 1195/4885L3MBTL1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.